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ABSTRACT

RALLI, GARYFALLIA. Blocking the entry of HIV by co-receptor inhibition.
ADVISOR: LEE PEDZISA
The goal of our project is to synthesize a dual CXCR4/CCR5 co-receptor inhibitor to block
the entry of HIV into host cells. In the early phase of the HIV-1 replication cycle, HIV-1
binds to host cells through the CD4 protein present on the host cell surface. To infect the
cell, HIV-1 requires further interactions that promote fusion of the viral and cellular
membranes. This can occur through binding to the chemokine co-receptors such as CXCR4
and CCR5. We are choosing dual inhibition since under selective pressure of a CCR5
antagonist, CXCR4-using strains have been shown to predominate. Through dual
inhibition, we want to minimize possible resistance development that could occur when
inhibiting only one of the two co-receptors.
Using a computational screen, a compound predicted to bind to both CCR5 and CXCR4
was identified (Hit 1). We established a reaction scheme to synthesize an analog of this
compound (target compound 4) through solid phase peptide synthesis. We confirmed the
successful synthesis of this compound through LCMS and HPLC.
We also made progress towards synthesizing two analogs of target compound (4) by
varying the last Fmoc-phenylalanine. The first analog contained Fmoc-4-fluorophenylalanine while the second analog contained Fmoc-4-methoxy-phenylalanine.
Lastly, we ran a docking screen to determine FDA approved compounds that could be
repurposed as potential CCR5 inhibitors. In this, 40 compounds were identified to bind
CCR5 with a higher affinity than FDA-approved CCR5 inhibitor, Maraviroc.
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CHAPTER 1: INTRODUCTION
1.1 AIDS and HIV
Acquired

immunodeficiency

syndrome

(AIDS)

caused

by

the

human

immunodeficiency virus (HIV), is a disease of the human immune system that poses a great
public health threat (Sharp and Hahn, 2011). AIDS, a chronic disease, is triggered by HIV
infection and ultimately leads to the collapse of the immune system, signaled by CD4-Tlymphocyte cell depletion (Chatterjee et al., 2012). The course of the infection varies
among individuals. Some individuals remain clinically and immunologically healthy for
ten or more years after the infection while others progress to AIDS as early as one year
after HIV infection (Chatterjee et al., 2012). Since its discovery, HIV has infected
approximately 79.3 million people and has claimed around 36.3 million lives (UNAIDS,
2020). In 2020, 37.7 million people were living with HIV and 68 thousand lives were lost
to an AIDS-related disease (UNAIDS, 2020). Therefore, a preventive or therapeutic
treatment for AIDS is of big importance.
HIV is a retrovirus with a complex genome and a cone-shaped capsid core particle.
Its genome is encoded by RNA and it is reversely transcribed to DNA by reverse
transcriptase (RT) upon entering a host cell (Turner and Summers, 1999). The virus falls
into two categories, HIV-type 1 (HIV-1) and HIV-type 2 (HIV-2), with HIV-1 being the
main agent of AIDS. However, the viral structure is similar for both types of HIV (FanalesBelasio et. al, 2010).
1.2 HIV replication cycle
During the early phase of the HIV replication cycle, HIV-1 binds to host cells
through the CD4 protein (receptor protein) present on the host cell surface, which is
1

otherwise important for the immune system (Figure 1). To infect the cell, HIV-1 requires
further interactions that promote fusion of the viral and cellular membranes. This can occur
through binding to the chemokine co-receptors such as CXCR4 and CCR5 (co-receptor
proteins). Upon entering the host cell, reverse transcription of the viral RNA is catalyzed
in the cytosol by reverse transcriptase. The viral DNA is then transported to the nucleus; a
complex process aided by various proteins. Finally, the viral DNA is integrated into the
host genome by integrase. The late phase of the HIV-1 life cycle starts as the mRNA
transcripts are transported out of the nucleus for translation. The structural proteins
resulting from this process rearrange to form the virus, a process called maturation. (Turner
and Summers, 1999).

Figure 1. Summary of the early phase of the HIV replication cycle (Moore and
Stevenson, 2000).
2

1.3 HIV infection process
The infection process is initiated when HIV binds to the CD4 protein on the surface
of the host cell (Figure 2). The binding occurs through interactions between the virus’s
surface glycoprotein gp120 and CD4. The envelope glycoprotein is synthesized after the
cleaving of gp160, an oligomeric precursor protein. The cleaving results in gp120, which
is the surface subunit responsible for binding to receptor CD4 and co-receptors
CXCR4/CCR5, and in gp41, responsible for membrane fusion (Feng et al., 1996). Gp120
includes an inner domain interacting with gp41 and an outer domain, which interacts with
CD4/ CXCR4 & CCR5 for host cell infection (Kwong et al., 1998). Gp41 has an
extracellular, transmembrane, and cytoplasmic domain with the extracellular domain
including the fusion peptide (FP) (Garg et al., 2011).
Binding to CD4 causes a conformational change in the viral gp120, which exposes
the chemokine receptor binding sites and, thus, promotes further interaction with the
chemokine co-receptors (CXCR4 or CCR5). Consequently, the interactions with the
chemokine co-receptors trigger a series of conformational changes that encourage the
fusion of the viral and cellular membranes (Chen, 2019; Turner and Summers, 1999). In
this process, the fusion peptide is necessary for successful infection. Due to its hydrophobic
character, it can be embedded into the host cell membrane upon the triggering of fusion.
Gp120 binding to CD4 causes the exposure of the co-receptor binding site and the
displacement of the fusion peptide towards the membrane of the host cell (Blumenthal et
al., 2012; Contarino et al., 2013; Eckert and Kim, 2001). A series of conformational
changes in gp41 bring the viral and host cell membranes together (Blumenthal et al., 2012;
Contarino et al., 2013; Eckert and Kim, 2001).
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Figure 2. The fusion process for the trimeric HIV-1 envelope glycoprotein
complex is depicted in schematic form. The sequential binding of the gp120 moieties
(yellow ovals) to CD4 and a co-receptor on the cell membrane (not shown) drives
conformational changes in the gp41 moieties (dark blue ovals). These changes cause the
N-peptide region of gp41 (light blue cylinders) to translocate, and the fusion peptide (red
lines) to insert into the cell membrane, forming the ‘pre-hairpin intermediate’.
Subsequent conformational changes in gp41 may be necessary to create the ‘hairpin
form’ in which the viral and cellular membranes are brought into close enough proximity
for membrane coalescence and fusion to occur (adapted from Moore and Stevenson,
2000).
Interestingly, some HIV-1 strains bind preferentially to the CCR5 receptor (Mtropic or R5-tropic) while others use CXCR4 (T-tropic or X4-tropic) (Figure 3). However,
there are also some strains that can bind to both receptors, CCR5 and CXCR4 (dual tropic)
4

(Fanales-Belasio et. al, 2010). Although years after transmission the CXCR4 co-receptor
can be used to facilitate infection too, during early infection R5-tropic viruses dominate
(Connell et al., 2020) (Figure 4). R5-tropic HIV-1 viruses have a higher affinity for the
CD4 receptor. In early infection CD4+ memory T-cells, which have a high expression of
CCR5 on their cell surface, are the primary target of HIV-1. As the disease progresses,
memory T-cells become depleted which allows targeting of naive CD4+ T-cells with
predominantly CXCR4 co-receptors on their cell surface. In this way, it becomes clear that
X4-tropic viruses are not the dominant viral phenotype. However, they can be present as a
minority and rapidly multiply if R5-tropic viruses are inhibited. Maraviroc, a CCR5
antagonist, presents an example of this as X4-tropic viruses rapidly increase when the drug
is present and are reduced to a minority again when the drug is discontinued (Connell et
al., 2020).

Figure 3. HIV tropism. In panel A a T-tropic (X4 tropic) HIV virus binds to a CXCR-4
coreceptor while a M-tropic (R5 tropic) HIV virus is unable to bind. In panel B a Mtropic HIV virus binds to a CCR-5 coreceptor while a T-tropic HIV virus is unable to
bind (Fanales et al., 2010).

5

Figure 4. Cellular tropism Naive CD4+ T cells are CXCR4+ and CCR5–, and rarely
infected by R5 virus. R5 HIV-1 strains are commonly transmitted and persist during the
course of infection but might evolve to dual tropic (D) or mixed (M) virus populations,
and to X4 phenotype at late stages of disease. Of treatment-naive individuals, 12–19%
have dual or mixed viral populations, and less than 1% are infected with X4 viruses. Of
treatment-experienced individuals, 22–48% have dual or mixed viral populations, and 2–
4% are infected with X4 viruses (adapted from Este and Talenti, 2007).
1.4 HIV Treatments
When it comes to the treatment of HIV, its variability allows it to overcome host
immunity and drug and vaccine effects. This variability occurs through the error-prone
mechanism of reverse transcriptase, the rapid viral replication, and the possibility of
recombination of two or more different HIV viruses (Fanales-Belasio et. al, 2010).
However, the error-prone mechanism of the enzyme reverse transcriptase has been
recognized as the main cause of drug resistance development in HIV (Moyle, 1997).
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In general, mutations can significantly reduce or increase viral fitness, but they can
also turn out not to have any effects on the virus. Particularly, for drug resistance to occur
due to a mutation, the coding region of the therapeutic agent’s target must mutate in a way
that the region’s resulting protein remains active even in the presence of the drug.
Mutations can also be transmitted from one person to another through transmission of
mutated HIV (Najera et al., 1995). Importantly, mutations that result in resistance to
multiple therapeutic agents can pose a significant problem. Specifically, this became
apparent in the early days of HIV treatment when monotherapy, treatment with a single
agent, was used. Monotherapy is more likely to result in resistant isolates. In this way, the
importance of combination therapy for HIV-1 became apparent (Hirsch et al, 1998).
Combining antiretroviral drugs can have several potential benefits and drawbacks.
Two drugs in combination may allow for reducing the dosage needed for each drug while
still achieving the desired effects. On the other hand, the combination of two drugs can
lead to side-effects not associated with any of the two drugs individually. Combination
therapy can also influence drug resistance development. More specifically, the two drugs
can be effective while using different mechanisms of action. In this way, resistance
development may be less likely to occur and in case it occurs, it is likely to have a lesser
impact than in the case of monotherapy. Lower dosages may also contribute to resistance
development being less likely. However, a mutation that leads to resistance to both drugs
can be detrimental to the treatment (Pirrone et al., 2011).
Highly active antiretroviral therapy (HAART) is an HIV treatment approach, which
includes the administration of a combination of three or more antiretroviral drugs. In doing
so, the main goal is to inhibit HIV replication through multiple different mechanisms so
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that resistance to one of the administered agents can be counteracted by the other ones
present (Cunningham et al., 1999; Kitahata et al., 1996; Rackal et al., 2011; Shafer et al.,
1999).

Figure 5. Summary of the HIV antiretroviral drug classes along with the drugs
that fall under each class (Pirrone et al., 2011).
There are five classes of combination antiretroviral therapy drugs that impact
different phases of the HIV-1 life cycle (Figure 5). The first class contains agents that block
viral entry into the host cell (entry inhibitors) by interfering with chemokine receptors or
membrane fusion. The second class terminates viral replication using nucleoside reverse
transcription inhibitors (NRTIs). The third one, non-nucleoside reverse transcription
inhibitors (NNRTIs), also terminates viral replication by binding to a different site than
NRTIs. The agents of the fourth class, integrase strand transfer inhibitors (INSTIs) inhibit
integration of the viral DNA into the host cell genome and the agents of the last class
interfere with protease activity, which is responsible for assembling the new virus (Protease
inhibitors, PIs) (Atta et al., 2019). The standard HAART combination for most patients
8

includes two NRTIs and one NNRTI or INSTI. (Günthard et al., 2016; Ford et al., 2018;
Thompson, et al., 2012).
1.5 HIV entry inhibitors
Currently there are four FDA approved entry inhibitors. Enfuvirtide (2003) is a
fusion inhibitor, which blocks HIV from entering CD4 cells (NIH, 2021). It does so by
mimicking amino acids 127-162 on gp41 and interfering with membrane fusion of the HIV
and host-cell membranes (Este and Telenti, 2007). Fostemsavir (2020) is an attachment
inhibitor that binds to gp120 and prevents HIV from entering CD4 cells. Ibalizumab-uiyk
(2018), a post-attachment inhibitor, binds to CD4 receptors and, thus, does not allow HIV
to bind to coreceptors CCR5/CXCR4. Lastly, maraviroc (2007) is a CCR5 coreceptor
inhibitor. It acts as an allosteric, non-competitive inhibitor and blocks the entry of HIV into
the host cells (Este and Talenti, 2007; Latinovic et. al, 2019). A complete timeline of the
medicines approved by the FDA for HIV-treatment can be seen in Figure 6. As becomes
clear in this figure, when compared to the variety of protease and reverse transcriptase
inhibitors, there are very few entry and integrase inhibitors. As discussed, HAART relies
on attacking multiple pathways in the HIV cycle, therefore, there remains a need to
diversify HIV drugs.
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Figure 6. A timeline of the medicines approved by the FDA for HIV treatment
(NIH, 2021).
1.6 Maraviroc and resistance mechanisms
Maraviroc is currently the only coreceptor inhibitor approved by the FDA. It acts by
locking CCR5 into a conformation that HIV cannot bind and, thus, inhibits entry of R5
tropic HIV into host cells. However, maraviroc does not have any major effects in patients
10

infected with X4 and dual tropic HIV (Este and Talenti, 2007; Hardy et al., 2010; Latinovic
et. al, 2019; Sierra-Madero et al., 2010). One resistance mechanism to Maraviroc involves
selection for a minority of HIV viruses present in the organism that utilize CXCR4 for host
cell entry (Westby et al., 2006). As described above, Maraviroc therapy presents an
example of how X4-tropic viruses can rapidly expand under selection pressure and are
reduced to a minority again when the pressure is discontinued (Connell et al., 2020).
Another resistance mechanism selects for mutations that alter coreceptor use from CCR5
to CXCR4 (Nedellec et al., 2011). Therefore, the importance of dual inhibition of both
CXCR4 and CCR5 coreceptors has been emphasized in order to improve therapeutic
strategies against HIV (Horuk, 2009; Princen et al., 2004).
1.7 Repurposing screening
Another way of developing novel therapeutics is drug repurposing. Drug repurposing has
the potential to utilize medications with established safety profiles to target new patient
populations with conditions different than what the medication was originally meant to
address (Cha et al., 2018). Drug repurposing can reduce the high cost and time
requirements associated with drug discovery. Additionally, in drug discovery and
development, there is approximately 45% chance of failure connected to safety and toxicity
issues. All the above can be mitigated through drug repurposing. This process also offers
significant advantages to patients as they are able to gain access to novel treatments with
well analyzed safetery profiles faster (Asburn and Thor, 2004). An example of a repurposed
drug is azidothymidine, which was originally designed as a chemotherapy agent but
developed to be an HIV medication instead (Volberding et al., 1990).
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Repurposing approaches can be divided into two categories; experimental screening
approaches and in silico approaches. Molecular docking is an important in silico method
in predicting how chemical compounds can interact with a target. Therefore, this method
has proven to be useful in drug discovery and drug development. More specifically,
molecular docking utilizes the 3D structure of a compound of interest and predicts its
orientation when interacting with a biological target, such as a protein. Then, the
complementarity between the two is scored (Kitchen et al., 2004). In this way, based on
the docking score, we can determine which compounds are predicted to have a high binding
affinity for the protein of interest. Additionally, we can analyze the favorable ligandreceptor interactions.

1.8 Project Objectives
Using a docking approach, Professor Lee Pedzisa
identified a compound that is predicted to bind to both CCR5
and CXCR4 (Hit 1). We plan to synthesize analogs of Hit 1,
starting with target compound (4), using solid phase synthesis.
After achieving a satisfying number of compounds, we will evaluate
our inhibitors for biological activity if time permits. Specifically, we
will evaluate how well the ligands bind to CCR5 and CXCR4, how
specific the synthesized target compounds are to these co-receptors,
whether the compounds inhibit the co-receptors and ultimately
whether the compounds reduce viral entry into cells.
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Additionally, we want to run a new docking screen to analyze how FDA approved
compounds could potentially be repurposed as CXCR4 and CCR5 inhibitors.
Goals of the project summarized:
1.

Synthesize target compound (4) for CCR5 & CXCR4 dual inhibition.

2.

Synthesize analogs of the target compound.

3.

Test for biological activity:

-

Evaluate ligand binding to CCR5 and CXCR4.

-

Evaluate the specificity of the synthesized target compounds.

4.

Screen FDA approved compounds to be repurposed as potential CXCR4 and CCR5
inhibitors.
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CHAPTER 2: RESULTS AND DISCUSSION
2.1 Solid phase synthesis: target compound (4)
Our first goal was to establish a robust and effective solid phase
synthesis method of compound (4), which is an analog of the small
polypeptide predicted to bind both CXCR4 and CCR5. To do this, we
used rink amide MBHA resin beads as our basic building block where
all the amino acids were added one after the other. We based our
procedure on Nefzi and Santos (2006).
We started by neutralizing our rink amide MBHA resin beads with 10% DIEA/DMF
overnight. In the original paper by Nefzi and Santos (2006), neutralization with 5%
DIEA/DCM overnight was suggested. However, we determined that 5% DIEA/DMF
overnight did not lead to bead neutralization based on a p-chloranil amine test (Vojkovsky,
1995). Upon neutralization, the first amino acid, Fmoc-Phe-OH, was added as summarized
in Reaction Scheme 1.

Reaction Scheme 1. Addition of the first amino acid, Fmoc-Phe-OH. The reaction
conditions are indicated above and below the arrow. The chemical formula and exact
mass are reported.
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To confirm that the desired product was obtained from the solid phase synthesis, we
collected and cleaved a small sample of our beads to analyze by LCMS and HPLC. Since
our product is non-polar, a gradient of 5%-95% ACN with 0.1% formic acid was selected
to increase retention time. In spectrum 1 below, a peak can be identified at approximately
13 minutes. The identified peak corresponds to the exact mass of our desired product plus
1 (Reaction Scheme 1). This indicated that the product picked up a hydrogen cation (+1
charge) resulting in a peak corresponding to 387. Thus, successful addition of the first
amino acid was confirmed.

Spectrum 1. Spectrum obtained in the LCMS after addition of the first amino acid (FmocPhe-OH, Reaction Scheme 1). The prominent peak at 13 min (highlighted yellow)
corresponds to 387.
We also checked for a charge of +23, which can result from picking up a sodium cation.
Based on spectrum 1, we would expect a peak at approximately the same retention time
(13 minutes) to confidently say that some of our product also picked up sodium ions. As
shown in spectrum 2, a peak at approximately 13 minutes can be identified in this case as
well supporting, thus, our expectations.
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Spectrum 2. Spectrum obtained in the LCMS after addition of the first amino acid (FmocPhe-OH, Reaction Scheme 1). The peak at 13 min (highlighted yellow) corresponds to
409.
In both cases, the peak of interest in our spectra is not the only peak present. This could
point to multiple ionizable molecules present in our solution.
The purity of our product can be evaluated upon obtaining HPLC spectra. As seen in
Spectrum 3, there are two dominant peaks. Both of them are close to the retention time of
13min. Therefore, either one of them could represent the resulting product after addition
of the first Fmoc-PheOH (Reaction Scheme 1).

Spectrum 3. Spectrum obtained in the HPLC after addition of the first amino acid (FmocPhe-OH, Reaction Scheme 1).

Additionally, the presence of two peaks points to possible impurities associated with our
product synthesis. An explanation could be found in the way our sample for the
19

LCMS/HPLC was prepared. We cleaved our beads with TFA, separated the solution from
the beads and left the solution open to air to evaporate and avoid corrosion of any
instrument parts that could be caused by the TFA. After, we dissolved the resulting
precipitate using DMF. However, the DMF used was not LCMS/HPLC grade, leading us
to the conclusion that it could contain impurities. To test this possible explanation in the
future, LCMS/HPLC grade DMF can be used. Additionally, we could determine the mass
of the purity and predict what this impurity may be.
Upon completing the analysis of our first step in synthesis, the Fmoc group was removed
using 25% piperidine/DMF before adding the next amino acid. Following the procedure
described above and in the Experimental section (Chapter 3), we added three more amino
acids (Fmoc-proline, Fmoc-PheOH and Fmoc-PheOH). The steps for adding these amino
acids are summarized in Reaction Scheme 2 using the example of Fmoc-proline. For the
addition of Fmoc-proline, the LCMS spectrum can be found in the Appendix. Specifically,
a peak at approximately 13min corresponding to 484 (exact mass +1) can be identified
confirming successful synthesis. Additionally, both the LCMS and HPLC spectrum for the
addition of the second Fmoc-Phe-OH can be found in the Appendix. In the LCMS
spectrum, a peak for both 631 (exact mass +1) and 653 (exact mass +23) can be found at
approximately 22min. Similarly, in the HPLC, a prominent peak was identified at 21.5
min.
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Reaction Scheme 2. Deprotection and addition of Fmoc-proline. The reaction conditions
are indicated above and below the arrow. The chemical formula and exact mass are
reported.

Upon addition of the last amino acid, our product was N-acetylated with phenylacetic acid
as presented in Reaction Scheme 5. The addition of phenylacetic acid had a longer duration
as it was run overnight.

Reaction Scheme 3. N-acetylation with phenylacetic acid. The reaction conditions are
indicated above and below the arrow. The chemical formula and exact mass are reported.
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Then, the amide bonds were reduced using BH3/THF (Reaction Scheme 6). This reaction
proved to be challenging. Reaction time was very important. Specifically, when the beads
were left in BH3/THF for longer than 72 hours, we observed decomposition. This becomes
apparent due to the presence of a white cloud in the otherwise yellow solution.
Additionally, the reduction reaction is extremely sensitive to oxygen and moisture since
BH3 is unstable and very reactive and THF is anhydrous. For this reason, we left the
glassware used for the reaction to dry overnight in the oven to reduce moisture. Moreover,
during the preparation for the reaction and the reaction run, we had to make sure that
BH3 had minimal contact with oxygen by constantly purging the reaction with nitrogen and
sealing the glassware fast. Another challenge was transferring the beads from the syringe
used for solid phase synthesis to the round bottom flask for the reduction reaction. To do
this, we used THF suspend the beads, transfer most of them and then wash the syringe.
After completion of the reduction reaction, leftover BH 3 needed to be quenched with
methanol and disproportioned with piperidine, as described in detail in the Experimental
section.
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Reaction Scheme 4. Amide reduction with BH 3/THF. The reaction conditions are
indicated above and below the arrow. The chemical formula and exact mass are reported.
Then, the resin-bound polyamines were treated with thiocarbonyldiimidazole for
cyclization (Reaction Scheme 7, step 1). Finally, they were cleaved from the resin using
99% TFA (Reaction Scheme 7, step 2). The resulting solution containing the polypeptide
was diluted with acetonitrile and water and lyophilized to obtain a powder-like, white
substance. The successful synthesis of the desired polypeptide was confirmed through
LCMS (Appendix). A peak corresponding to 710 (exact mass +23) can be seen at
approximately 19min and confirms the synthesis of target compound 4. Unfortunately, we
were not able to obtain LCMS and HPLC spectra for all our intermediate steps. In the
future, this is something that we would like to address in order to further support the
reliability of our synthesis procedure.
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Reaction Scheme 5. Polyamines treated with thiocarbonyldiimidazole. The reaction
conditions are indicated above and below the arrow. The chemical formula and exact
mass are reported.

2.2 Solid phases synthesis: further analogs by varying amino acids

Upon successful synthesis of the aforementioned analog, we
proceeded by planning the synthesis of two more analogs through
varying the last Fmoc-phenylalanine. The goal of synthesizing
analogs is to optimize CXCR4/CCR5 dual inhibition.
For the first analog, we decided to substitute the last Fmoc-Phe-OH
with a 4-fluoro-Fmoc-phenylalanine. For our second analog, we
chose to substitute with 4-methoxy-Fmoc-phenylalanine. Both the
fluoro- and the methoxy-group could enhance chemokine receptor
binding due to the polypeptide occupying more space and due to
additional hydrogen bonding.
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The procedure used to synthesize these analogs was the same as the one used to synthesize
target compound 4, outlined above and in the Experimental section. We faced some
challenges while synthesizing the two analogs. Both analogs decomposed during the
reduction reaction with BH3/THF. A possible explanation for this can be inferred from the
observation that solvent evaporated during the 72h of the reaction. Specifically, after 72h,
one of the round bottom flasks used had no solvent left in it while the other had very little
solvent left. This led us to conclude that the septum was not tight enough and, thus, the
solvent evaporated and escaped. During the 72h, the constantly decreasing solvent volume
due to evaporation led to increasing concentration of BH 3 and this could have decomposed
the beads. This incident further underlines the challenging nature of the reduction reaction
for this synthesis.

2.3 AutoDock Vina Virtual Screening of positive control ligand Maraviroc
In addition to synthesizing a target from a previous computational screen, we wanted to
screen FDA approved compounds against chemokine co-receptors CXCR4 and CCR5. The
advantage of FDA approved compounds is that they have passed toxicity and stability tests
and are ready for administration. In this way, we hoped to identify FDA approved
compounds that could be used as potential inhibitors of these two co-receptor proteins.
We started by downloading the CCR5 co-receptor protein with bound Maraviroc from the
Protein Data Bank (4MBS). Then, we prepared our protein using Discovery Studio and
Autodock as described in Experimental 3.3.3 (Chapter 3). The resulting protein is presented
in Figure 7 with its binding site indicated by the yellow sphere.
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Figure 7. Prepared CCR5 co-receptor protein;
the binding site is indicated by the yellow sphere.
To establish a baseline for the binding affinities in our experiment, we docked a known
CCR5 inhibitor, Maraviroc, against our prepared CCR5 co-receptor protein. The ligand
was prepared according to Experimental 3.3.5. This yielded a binding affinity of -9.2
kcal/mol. To evaluate the effectiveness of our protein preparation method and to further
analyze ligand binding, we compared the orientation of bound Maraviroc from our 4MBS
file to the orientation of bound Maraviroc resulting from our docking experiment. In Figure
8, the Maraviroc configuration resulting from docking can be seen in yellow whereas the
native Maraviroc configuration (4MBS) can be seen in gray. The upper domain of
Maraviroc resulting from screening (yellow), the area indicated by the white line, shows a
relatively good overlap with the native Maraviroc (gray). More differences in orientation
can be observed in the lower parts of the molecules (indicated by the yellow arrow).
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Figure 8. Comparison of 4MBS bound Maraviroc (native conformation - gray) with
Maraviroc resulting from screening (yellow).
Although native and screen Maraviroc binding were not identical, we decided to move
forward by using the protein preparation outlined in Experimental 3.3.3. Additionally, we
decided to include additional positive controls in our FDA ligands screen. We included 16
CCR5 inhibitors with known IC50s such as Vicriviroc. In addition to having known IC50s,
some of these compounds have undergone clinical trial indicating that they have
efficacious binding affinities. In this way, we hoped to have more points of reference to
compare the binding of our FDA ligands to.

2.4 AutoDock Vina Virtual Screening of FDA approved ligands
We proceeded by screening 1614 FDA approved compounds obtained from the Zinc
database against our prepared CCR5 co-receptor protein in the Maraviroc binding site. The
FDA ligands were prepared according to Experimental 3.3.7. The screen took
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approximately a week to complete (Experimental 3.3.8), and the results were analyzed
according to Experimental 3.3.9. Our screen yielded 40 compounds that were predicted to
bind CCR5 with a higher or equal affinity to Maraviroc (Table 1).

Table 1. FDA approved compounds identified by virtual screen to bind CCR5 with a
higher/equal affinity than/as FDA-approved CCR5 inhibitor, Maraviroc.
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The compounds that ranked from the 2nd to the 6th place based on binding affinity were
identified

as

Adapalene

(-10.9

kcal/mol),

Naldemidine

(-10.8

kcal/mol),

Dihydroergotamine (-10 kcal/mol), Olaparib (-9.9 kcal/mol) and Naftifine (-9.0 kcal/mol)
accordingly. A challenge we faced while trying to identify the top ranked compounds was
bonds being altered due to possible file corruption either during the protein preparation
process or the run. Due to this, we were unable to identify compound 406 (first place
ranking).

2.5 Highest CCR5 binding affinity FDA approved ligands analysis
Rank 2: Adapalene
The first FDA approved compound we identified was adapalene. The structure of
adapalene can be found in Figure 8.
O

OH

O

Figure 8. Adapalene structure.
Adapalene is a synthetic retinoid and a very effective acne treatment option (Cunliffe et
al., 1997). Adapalene is better tolerated than other synthetic retinoids used to treat acne
(Schaefer and Reichert, 1990). Specifically, it acts as an acne treatment by having an effect
on cell proliferation and differentiation as well anti-inflammatory properties. It does so by
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interacting with retinoic acid receptors (RARα, RARβ, RARγ) and with 9cis-retinoic acid
receptors (RXRAα, RXRAβ, RXRAγ) (Michel et al., 1998). A common brand currently on
the market containing adapalene is the Differin Gel. Adapalene has not been tested in the
context of HIV entry inhibition.
Our repurposing screening identified adapalene as one of the compounds with the highest
CCR5 binding affinity (Table 1). This makes adapalene an interesting compound to further
investigate in the context of chemokine co-receptor inhibition. In Figure 9A, adapalene is
shown bound to co-receptor CCR5 in the same binding site used by Maraviroc. Panel B
shows the interactions between adapalene and the amino acids present in the CCR5 binding
site. All interactions between adapalene and CCR5 are hydrophobic.

Figure 9. Adapalene bound to chemokine co-receptor CCR5. Panel A shows the
orientation of adapalene in the CCR5 binding site. Panel B shows the interactions
between adapalene and the amino acids present in the CCR5 binding site.
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Rank 3: Naldemedine
Naldemedine was the FDA approved compound with the third highest affinity binding
ranking (Table 1, Figure 10).

Figure 10. Structure of naldemedine.
Naldemedine (Symproic in Japan/US, Rizmoic in EU) is an μ-opioid receptor antagonist.
It is used to increase bowel movement in opioid induced constipation, which is caused by
opioid treatment for cancer pain or for chronic non-cancer pain (Blair, 2019). Naldemedine
acts on opioid receptors in the gastrointestinal tract and it is generally well-tolerated. Its
possible side effects are related to gastrointestinal function (Markham, 2017). Naldemedine
has not been investigated in relation to HIV.
Our virtual screen determined naldemedine as a possible CCR5 inhibitor. In Figure 11,
panel A shows naldemedine bound to CCR5. Naldemedine interacts with CCR5 through
hydrophobic interactions and van der Waals interactions (fade green) (Figure 11B).
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Figure 11. Naldemedine bound to chemokine co-receptor CCR5. Panel A shows the
orientation of naldemedine in the CCR5 binding site. Panel B shows the interactions
between naldemedine and the amino acids present in the CCR5 binding site.

Rank 4: Dihydroergotamine
Dihydroergotamine was the next FDA approved compound we identified (Table 1, Figure
12).

Figure 12. Structure of dihydroergotamine.
Dihydroergotamine belongs to the family of ergot alkaloids, a group with many
pharmacological effects (Silberstein, 1997). Dihydroergotamine can be synthesized from
ergotamine by reducing an unsaturated bond. Both ergotamine and dihydroergotamine are
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used to treat migraines. They do so by acting as antagonists to receptors 5-HT1B, 5-HT1D
and 5-HT1F (Silberstein and McCrory, 2002). However, both compounds also have
adverse effects due to their interactions with other monoamine receptors. This can cause
nausea, vomiting and other reactions (Silberstein and McCrory, 2002). In the context of
HIV, it is advised to not co-administer dihydroergotamine with ritonavir, an HIV protease
inhibitor, as this can lead to acute ergot toxicity (Mohamedi et al., 2021).
The results showed dihydroergotamine to be the compound with the fourth highest CCR5
binding affinity (Table 1). Figure 13A shows dihydroergotamine bound to CCR5 while
Panel B presents the interactions between dihydroergotamine and CCR5 binding site amino
acids. Dihydroergotamine interacts hydrophobically with the amino acids shown in pink.
It also shows a pi-anion interaction with Glu282 (orange).

Figure 13. Dihydroergotamine bound to chemokine co-receptor CCR5. Panel A shows
the orientation of dihydroergotamine in the CCR5 binding site. Panel B shows the
interactions between dihydroergotamine and the amino acids present in the CCR5
binding site.
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Rank 5: Olaparib
Olaparib is used as a treatment option in ovarian and other types of cancer. It is a polyADP-ribose polymerase inhibitor (Figure 14). Specifically, it acts at the catalytic site of
enzymes PARP1 and PARP2 as an NAD+ competitive inhibitor (Robson et al., 2017).
These enzymes are important in DNA repair. By inhibiting them, olaparib inhibits DNA
repair and induces cell death (Bochum et al., 2018). Olaparib treatment had not been
reported in the context of HIV.

Figure 14. Structure of olaparib.
Our screen ranked olaparib in the fifth place for CCR5 binding affinity (Table 1). Olaparib
interacts with CCR5 through hydrophobic interactions. Additionally, it shows pi-anion
interactions with Glu283 (orange) (Figure 13). This interaction was previously observed in
dihydroergotamine (Figure 15).
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Figure 15. Olaparib bound to chemokine co-receptor CCR5. Panel A shows the
orientation of olaparib in the CCR5 binding site. Panel B shows the interactions between
olaparib and the amino acids present in the CCR5 binding site.

Rank 6: Naftifine
Naftifine is the last FDA approved ligand we looked further into (Table 1, Figure 16).
Naftifine is an allylamine derivative that is used as an antifungal. It can be administered as
a topical gel, which is well tolerated with topical irritation occurring in some cases (Monk
and Brodgen, 2012; Mühlbacher, 1991). Naftifine works by inhibiting squalene epoxidase,
which leads to inhibition of ergosterol synthesis (Monk and Brodgen, 2012). Naftifine has
not been studied for HIV inhibition.
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Figure 16. Structure of naftifine.
In Figure 17A, naftifine is shown bound to the CCR5 Maraviroc binding site. As shown in
Panel B, naftifine interacts hydrophobically with the amino acids present in the binding
site (pink).

Figure 17. Naftifine bound to chemokine co-receptor CCR5. Panel A shows the
orientation of naftifine in the CCR5 binding site. Panel B shows the interactions between
naftifine and the amino acids present in the CCR5 binding site.
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CHAPTER 3: EXPERIMENTAL
3.1 Solid phase synthesis: target compound (4)
General information:
All amino acids, carboxylic acids, reagents and solvents were obtained commercially and
used without further purification. Solid phase synthesis was carried out in a polypropylene
syringe with a frit.

Synthesis overview for target compound (4)

We based our synthesis procedure on Nefzi and Santos (2006).
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Synthesis of (1)

Step 1: 50mg of MBHA (methylbenzyhdrylamine) resin was contained within a
polypropylene syringe with a frit. The amino-resin was neutralized with 10% DIEA
(diisopropylethylamine) in DMF (dimethylformamide) overnight (approx. 24h). The resin
was washed with DMF (2x10min). Fmoc-Phe-OH (6 equiv, 0.1M) was coupled in the
presence

of

HOBt

(hydroxybenzotriazole)

(6

equiv.,

0.1M)

and

DIC

(diisopropylcarbodiimide) (6 equiv., 0.1M) in anhydrous DMF (2mL) for 60 minutes. A
sample was collected to run in the LCMS and HPLC. To do this, the beads were cleaved
using 99% TFA (trifluoroacetic acid). Upon filtering, the solution was left open to air for
the TFA to evaporate overnight. The resulting precipitate was dissolved in DMF. For the
LCMS and HPLC an Agilent C18 column (Synergi Hydro-RP 80A LC Column) was used.
A continuous gradient of 5%-95% ACN (acetonitrile) with 0.1% formic acid and H2O with
0.1% formic acid was set to run for 20min with the percentage of ACN increasing over
time. The same procedure was followed for all LCMS and HPLC (Agilent Technologies
1100 and 1200 Series) runs.

Steps 2-3: The Fmoc group was then removed with 25% piperidine in DMF (2x10min) and
the resin was washed with DMF (8x). The free amine was coupled to Fmoc-proline
(6equiv, 0.1M) in the presence of HOBt (6 equiv., 0.1M) and DIC (6 equiv., 0.1M) in
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anhydrous DMF (2mL) for 60 minutes. A sample was collected to run in the LCMS and
HPLC.
Steps 4-5: The Fmoc group was then removed with 25% piperidine in DMF (2x10min) and
the resin was washed with DMF (8x). The free amine was coupled to Fmoc-Phe-OH
(6equiv, 0.1M) in the presence of HOBt (6 equiv., 0.1M) and DIC (6 equiv., 0.1M) in
anhydrous DMF (2mL) for 60 minutes. A sample was collected to run in the LCMS and
HPLC.
Steps 6-7: The Fmoc group was then removed with 25% piperidine in DMF (2x10min) and
the resin was washed with DMF (8x). The free amine was coupled to Fmoc-Phe-OH
(6equiv, 0.1M) in the presence of HOBt (6 equiv., 0.1M) and DIC (6 equiv., 0.1M) in
anhydrous DMF (2mL) for 60 minutes. A sample was collected to run in the LCMS and
HPLC.
Synthesis of (2)

Steps 8-9: The Fmoc group was then removed with 25% piperidine in DMF (2x10min) and
the resin was washed with DMF (8x). The free amine was N-acylated with phenylacetic
acid (10 equiv.) in the presence of HOBt (10 equiv.) and DIC (10 equiv.) in anhydrous
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DMF (2mL) overnight (approx. 24h). A sample was collected to run in the LCMS and
HPLC.
Synthesis of (3)

Steps 10-11: The amide reduction was performed in a 25mL pear flask under nitrogen. The
resin was treated with 1M BH3-THF (borane–tetrahydrofuran) (40-fold excess over each
amide bond). The tube was heated at 65 °C for 72 h, decanted, washed with THF, and any
remaining borane quenched with MeOH (methanol). The borane was disproportionated by
treatment with piperidine at 65 °C overnight (approx. 24h). The resin was then washed
with MeOH (2x), DMF (6x) and left open to air to dry overnight. A sample was collected
to run in the LCMS and HPLC.
Synthesis of (4)

Steps 12-13: The resin-bound polyamines were treated overnight with a 6-fold excess of
TCDI (thiocarbonyldiimidazole, 0.05 M) in anhydrous DMF. Following cleavage from the
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resin with 99% TFA, the desired product was diluted with acetonitrile/water (50:50) and
lyophilized. A sample was collected upon cleaving to run in the LCMS and HPLC.
Another sample was collected upon lyophilization (white-yellow powder, 0.0002g) of the
desired product to run in the LCMS and HPLC.

3.2 Solid phase synthesis: further analogs by varying amino acids
Synthesis of 4-fluoro-Fmoc-Phe-OH analog

For the synthesis of the 4-fluoro-Fmoc-Phe-OH analog the same procedure as outlined
above was used with the following modifications:
In the addition of the last amino acid (steps 6-7), Fmoc-Phe-OH was substituted with 4fluoro-Fmoc-Phe-OH (6 equiv.).
Unfortunately, our compound decomposed during the reduction reaction. The intermediate
we successfully obtained before the reduction reaction is shown above.
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Synthesis of 4-methoxy-Fmoc-Phe-OH analog

For the synthesis of the 4-methoxy-Fmoc-Phe-OH analog the same procedure as outlined
above was used with the following modifications:
In the addition of the last amino acid (steps 6-7), Fmoc-Phe-OH was substituted with 4methoxy-Fmoc-Phe-OH (6 equiv.).
Unfortunately, our compound decomposed during the reduction reaction. The intermediate
we successfully obtained before the reduction reaction is shown above.

We based our repurposing screening procedure on Danziger (2022).
3.3 Repurposing screening
Overview:
3.3.1 Necessary files for screening
3.3.2 Hardware and Software
3.3.3 Receptor protein preparation and Grid Box creation
3.3.4 Creating the configuration file (Notepad or other text editor)
3.3.5 Preparation of positive control ligands (Maraviroc)
3.3.6 AutoDock Vina Virtual Docking of one ligand
3.3.7 Preparation of FDA test ligands
3.3.8 AutoDock Vina Virtual Screening of FDA test ligands
3.3.9 Analysis of Virtual Screening Results for FDA test ligands
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3.3.1 Necessary files for screening


Prepared receptor protein in PDBQT format



Prepared positive control ligands in PDBQT format



Folder with prepared FDA approved compounds (test ligands)



FDA ligands text file



Configuration file with the receptor protein (and ligand if docking only one ligand)



Vina_windows.pl (to dock multiple ligands in the FDA text file)
(create a text file named Vina_windows.pl and copy the script below)
Script for Vina_windows is as follows:
#!/usr/bin/perl
print"Ligand_file:\t";
$ligfile=<STDIN>;
chomp $ligfile;
open (FH,$ligfile)||die "Cannot open file\n";
@arr_file=<FH>;
for($i=0;$i<@arr_file;$i++)
{
print"@arr_file[$i]\n";
@name=split(/\./,@arr_file[$i]);
}
for($i=0;$i<@arr_file;$i++)
{
chomp @arr_file[$i];
print"@arr_file[$i]\n";
system("vina.exe --config configFDA.txt --ligand @arr_file[$i] --log
@arr_file[$i]_log.log");
}

3.3.2 Hardware and Software


Computer/Laptop: Linux, Macintosh, or Windows PC



Notepad or other text editor



AutoDock4 (for protein preparation and visualization)



AutoDock Vina
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AutoDockTools (Part of MGLTools)



AutoLigand (Part of AutoDockTools)



BIOVIA Discovery Studio Visualizer (for protein/binding site preparation and
visualization)



Open Babel (for file conversions)



Ubuntu (for separating multiple ligands in one file)



Perl (for docking multiple ligands at once)

3.3.3 Receptor protein preparation and Grid Box creation


Download the receptor protein from the Protein Data Bank (https://www.rcsb.org/)



Type 4MBS (for the CCR5 chemokine receptor) in the search bar and download
protein as a PDB file

Discovery Studio (for protein editing and defining the binding site):


Open PDB receptor protein (4MBS) in Discovery Studio



View > Hierarchy to see protein chains, ligands, water molecules, etc.



Delete water molecules, cofactors, ions, etc. that should not be included in the
protein receptor for the run



Select ligand in the active site of interest:

Receptor-Ligand Interactions > Define and Edit Binding Site > From Current Selection.
A sphere defining the binding site will appear based on where your selected ligand is
located.


SBD Site Sphere > (right click) Attributes of SBD_Site_Sphere
1. Expand to include residues of interest by editing the radius.

45

2. Get x, y, z coordinates for the binding site.
For 4MBS: X,Y,Z → 149.854622, 108.414865, 22.290459
Radius = 10


Copy and paste grid dimensions (xyz and radius) into a new notepad file to be used
as the configuration file for the run (see 3.3.4 for further instructions on
configuration file preparation)



Close Attributes of SBD_Site_Sphere window by saving current grid dimensions



Delete any ligand groups and protein chains that were used for defining the SBD
site sphere but are not needed for the run



Chemistry > Hydrogens > Add Polar to add polar hydrogens



Save as PDB

Autodock (for further protein editing and conversion to PDBQT):


Open Autodock



Grid > Macromolecule > Open and use the “Files of type” menu to choose “all
files” and open the receptor protein file previously edited in Discovery Studio



Select your file > Open.



To further edit your receptor protein:

1. Edit > Hydrogens > Edit Histidine Hydrogens > HE2 (for all hydrogens) > Apply
> Dismiss
2. Edit > Charges > Add Kollman Charges
3. Edit > Misc > Check for Missing Atoms
4. Edit Charges > Check Totals on Residues > Spread Deficit Over All Atoms in
Residues
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Protein preparation is now done


Grid > Macromolecule > Choose > Save as PDBQT and place in docking folder
with ligands

3.3.4 Creating the configuration file (Notepad or other text editor)


Create a Notepad/text editor file (see 3.3.3)

Organize your notepad/text editor configuration file as shown below:
receptor = 4MBS.pdbqt
center_x = -12.661086
center_y = 31.554174
center_z = 45.079252
size_x = 10
size_y = 10
size_z = 10
num_modes = 10 (This specifies the maximum number of binding modes to generate)
energy_range = 4 (This specifies the energy difference between the best and the worst
binding mode)
exhaustiveness = 24 (This specifies the number of runs)


If docking only one ligand, include the ligand below the receptor:

receptor = 4MBS.pdbqt
ligand = Maraviroc.pdbqt
Save (as 4MBS_config.txt) and place in your working folder
3.3.5 Preparation of positive control ligands (here: Maraviroc)
Autodock:


Open Autodock



Go to: All Molecules > (right click) Read Molecule > select your ligand file
(Maraviroc) > Open
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To prepare your ligand:

1. Edit > Delete water
2. Edit > Charges > Add Kollman Charges
3. Edit > Charges > Compute Gasteiger
4. Ligand > Input > Choose > click on your ligand (Maraviroc) > Select Molecule for
AutoDock4
5. Ligand > Torsion Tree > Detect Root


To save the prepared ligand as PDBQT:

Ligand > Output > Save as PDBQT and place in your working folder
3.3.6 AutoDock Vina Virtual Docking for one ligand


Open the command terminal on your device

 Change the directory to your working folder by typing:
cd C:\Users\garyf\Desktop\Docking\4MBS

Run vina using the prepared configuration file and save the output as output.txt by
typing:
vina.exe --config 4MBS_config.txt --log output.txt


3.3.7 Preparation of FDA test ligands
The compounds were downloaded and minimized by Danziger (2022).


Create a separate working folder for all the pdbqt ligand files (FDAligands)

Ensure that the following files are also pasted in your working folder:


Autodock4.exe



Autogrid4.exe



4MBS_config.txt (configuration text file for receptor protein)



Vina.exe
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Vina_license.rtf



Vina_split.exe



Vina_windows.pl



4MBS.pdbqt (receptor protein)

3.3.8 AutoDock Vina Virtual Screening for FDA test ligands
FDA test ligands text file:


Create a Notepad/text editor file (FDAligands) in your working folder



Open the command terminal on your device

 Change the directory to your working folder by typing:
cd C:\Users\garyf\Desktop\Docking\CCR5 antagonists pdbqt


Copy the names of everything in your working folder into your FDAligands.txt file
by typing:

dir /B > FDAligands.txt


Remove the file names you do not need from your text file (only include PDBQT
ligands)

To run:
1. Type in command terminal (you have already directed it to your working folder):
perl Vina_windows.pl (this commands will ask you for the ligand file)
FDAligands.txt (this points to the ligand txt file you created above)
The run took approximately a week to complete
A results text file was generated for each FDA ligand
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3.3.9 Analysis of Virtual Screening Results for FDA test ligands
Compile all the resulting text files into one new text file:
Please note:
1. The tail command requires a Mac
2. The tail command reads the last (-n) lines [where n is the number of lines] of all
.log files in the folder and writes then onto (>) output file (output.txt)



Open the command terminal on your computer



Navigate to the working folder containing the FDA approved compounds log files
as previously shown



Compile all the resulting text files into one new text file by typing:
tail -12 *.log > ccr5_output.txt

To rank the compounds based on their binding affinities use the following Python code
(this creates an Excel document with ranking of the compound, binding affinity and
compound number):
#reads a text file and extracts binding energies
from openpyxl import Workbook
#Open the file to read
file = "/Users/leepedzisa/Desktop/Research/ccr5_output.txt"
# read by line numbers
def get_lines(fp, line_numbers):
return (x for i, x in enumerate(fp) if i in line_numbers)
def number_lines(file):
with open(file, 'r') as fp:
#count the number of lines
x = len(fp.readlines())
return x
#print(x)
def get_compounds(file):
compounds = []
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with open(file, 'r') as fp:
x = number_lines(file)
#read lines 2, 15, ..., < x
cmpd_lines = get_lines(fp, [i for i in range(0, x)])
for line in cmpd_lines:
cmpd_line = line.split()
if cmpd_line and cmpd_line[0][0] == "=":
cmpd_name = cmpd_line[1]
name_split = cmpd_name.split(".")
cmpd = name_split[0]
#cmpd = line.split()[1].split(".")[0]
compounds.append(cmpd)
return compounds
def get_energies(file):
energies = []
with open(file, 'r') as fp:
#read lines 2, 15, ..., < x
lines = get_lines(fp, [i for i in range(1, x)])
j = 0
for line in lines:
cmpd_energy = []
temp = line.split()
if temp and temp[0] == "1":
cmpd_energy.append(int(compounds[j]))
cmpd_energy.append(float(temp[1]))
energies.append(cmpd_energy)
j += 1
return energies
def print_energies(number):
if number <= len(energies):
for i in range(number):
print("Compound: ", sorted_energy[i][0], "\t\tRank: ",
i+1, "\tBinding energy: ", sorted_energy[i][1])
else:
for i in range(len(energies)):
print("Compound: ", sorted_energy[i][0], "\t\tRank: ",
i+1, "\tBinding energy: ", sorted_energy[i][1])
def write_xl(lst, number):
#method requires "from openpyxl import Workbook"
book = Workbook()
sheet = book.active
sheet["A1"] = "Rank"
sheet["B1"] = "Energy"
sheet["C1"] = "Compound"
for i in range(number):
sheet.cell(row = i+2, column = 1).value=i+1
sheet.cell(row = i+2, column = 2).value=lst[i][1]
sheet.cell(row = i+2, column = 3).value=lst[i][0]
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book.save("Test_energies.xlsx")
#Run functions
x = number_lines(file)
compounds = get_compounds(file)
energies = get_energies(file)
sorted_energy = sorted(energies, key=lambda x:x[1])
write_xl(sorted_energy, 100)
#print_energies(20)
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CHAPTER 4: CONCLUSIONS AND FUTURE WORK
In our project we successfully synthesized target compound (4) and following it to obtain
target (4). We also confirmed the synthesis of (4) using LCMS and HPLC. Additionally,
we made progress in the synthesis of two analogs through varying amino acids (4-fluoroFmoc-Phe-OH analog and 4-methoxy-Fmoc-Phe-OH analog). However, these analogs
decomposed during the reduction reaction. Thus, we would like to reattempt analog
synthesis and obtain the aforementioned compounds. Due to time constraints, we were
unable to test (4) for biological activity by evaluating its binding to CCR4 and CCR5 and
its specificity. Therefore, this is one of the steps we would like to investigate in the future.
We have already identified some resources that could aid us in this. As the docking screen
took longer than expected, we were also unable to screen the FDA approved compounds
against CXCR4. In the future, we would like to move forward with docking the FDA
ligands to CXCR4 as well. Lastly, it would be interesting to test the FDA ligands that
ranked high in CCR5 binding affinity in the lab. We could do this by obtaining these
compounds commercially and running a CCR5 binding assay.
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APPENDIX
Addition of fist Fmoc-Phe-OH
NHFmoc
O

NH

Chemical Formula: C24H22N2O3
Exact Mass: 386.16

LCMS spectra:
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HPLC spectra:

Addition of proline
FmocN
O
NH
O

NH

Chemical Formula: C29H29N3O4
Exact Mass: 483.22

LCMS spectra:
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Addition of second Fmoc-Phe-OH

LCMS spectra:
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HPLC spectra

Cyclization with CSIm2 (final step)

S

N
N
N

N

S
NH

Chemical Formula: C42H49N5S2
Exact Mass: 687.34

LCMS spectra:
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